Header Logo

Connection

GUILLERMO GARCIA-MANERO to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications GUILLERMO GARCIA-MANERO has written about Dose-Response Relationship, Drug.
GUILLERMO GARCIA-MANERO
Connection Strength
1.323
Dose-Response Relationship, Drug
  1. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun; 6(6):e317-e327.
    View in: PubMed
    Score: 0.096
  2. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019 Apr; 6(4):e194-e203.
    View in: PubMed
    Score: 0.095
  3. Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase?III?Trial. Clin Lymphoma Myeloma Leuk. 2019 04; 19(4):213-219.e4.
    View in: PubMed
    Score: 0.094
  4. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017 Dec 15; 123(24):4851-4859.
    View in: PubMed
    Score: 0.085
  5. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53.
    View in: PubMed
    Score: 0.064
  6. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol. 2010 Jul; 150(1):72-82.
    View in: PubMed
    Score: 0.051
  7. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008 Aug 15; 112(4):981-9.
    View in: PubMed
    Score: 0.045
  8. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008 Feb 01; 111(3):1060-6.
    View in: PubMed
    Score: 0.043
  9. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007 Oct 01; 110(7):2302-8.
    View in: PubMed
    Score: 0.042
  10. Modifying the epigenome as a therapeutic strategy in myelodysplasia. Hematology Am Soc Hematol Educ Program. 2007; 405-11.
    View in: PubMed
    Score: 0.041
  11. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood. 2006 Aug 15; 108(4):1174-82.
    View in: PubMed
    Score: 0.039
  12. A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica. 2002 Aug; 87(8):804-7.
    View in: PubMed
    Score: 0.030
  13. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021 12; 35(12):3542-3550.
    View in: PubMed
    Score: 0.028
  14. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492.
    View in: PubMed
    Score: 0.025
  15. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer. 2019 05 15; 125(10):1665-1673.
    View in: PubMed
    Score: 0.024
  16. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018 Dec; 5(12):e618-e627.
    View in: PubMed
    Score: 0.023
  17. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055.
    View in: PubMed
    Score: 0.023
  18. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421.
    View in: PubMed
    Score: 0.023
  19. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234.
    View in: PubMed
    Score: 0.022
  20. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
    View in: PubMed
    Score: 0.022
  21. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 10; 18(10):1317-1326.
    View in: PubMed
    Score: 0.021
  22. Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. Leuk Res. 2017 08; 59:85-92.
    View in: PubMed
    Score: 0.021
  23. Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation. Cancer Lett. 2016 07 28; 377(2):149-57.
    View in: PubMed
    Score: 0.019
  24. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016 06 15; 122(12):1871-9.
    View in: PubMed
    Score: 0.019
  25. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. PLoS One. 2015; 10(8):e0135520.
    View in: PubMed
    Score: 0.019
  26. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015 Apr; 90(4):276-81.
    View in: PubMed
    Score: 0.018
  27. Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine. Biomed Res Int. 2015; 2015:497597.
    View in: PubMed
    Score: 0.018
  28. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma. 2015 Feb; 56(2):390-4.
    View in: PubMed
    Score: 0.017
  29. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014 Mar; 73(3):495-501.
    View in: PubMed
    Score: 0.017
  30. Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S289-94.
    View in: PubMed
    Score: 0.016
  31. Randomized, dose-escalation study of the p38a MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 2013 Apr; 27(4):977-80.
    View in: PubMed
    Score: 0.015
  32. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin Drug Metab Toxicol. 2011 May; 7(5):661-72.
    View in: PubMed
    Score: 0.014
  33. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60.
    View in: PubMed
    Score: 0.013
  34. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer. 2007 Nov 01; 110(9):2000-6.
    View in: PubMed
    Score: 0.011
  35. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma. 2007 Feb; 48(2):283-9.
    View in: PubMed
    Score: 0.010
  36. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007 Jan 15; 109(2):248-55.
    View in: PubMed
    Score: 0.010
  37. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007 Jan 01; 109(1):52-7.
    View in: PubMed
    Score: 0.010
  38. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006 Aug 01; 12(15):4628-35.
    View in: PubMed
    Score: 0.010
  39. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006 Jun 15; 106(12):2645-51.
    View in: PubMed
    Score: 0.010
  40. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006 May 15; 66(10):5495-503.
    View in: PubMed
    Score: 0.010
  41. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006 Mar 01; 106(5):1090-8.
    View in: PubMed
    Score: 0.010
  42. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res. 2006 Jul; 30(7):813-22.
    View in: PubMed
    Score: 0.010
  43. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15; 11(18):6615-24.
    View in: PubMed
    Score: 0.009
  44. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005 Jun 10; 23(17):3948-56.
    View in: PubMed
    Score: 0.009
  45. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004 May 15; 10(10):3371-6.
    View in: PubMed
    Score: 0.009
  46. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer. 2004 Apr 01; 100(7):1449-58.
    View in: PubMed
    Score: 0.008
  47. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer. 2004 Feb 01; 100(3):581-9.
    View in: PubMed
    Score: 0.008
  48. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004 Mar 01; 103(5):1635-40.
    View in: PubMed
    Score: 0.008
  49. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer. 2003 Oct 01; 98(7):1430-7.
    View in: PubMed
    Score: 0.008
  50. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol. 2003 Mar 15; 21(6):1050-6.
    View in: PubMed
    Score: 0.008
  51. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003 Jan 15; 101(2):473-5.
    View in: PubMed
    Score: 0.008
  52. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clin Cancer Res. 2002 Jul; 8(7):2134-41.
    View in: PubMed
    Score: 0.007
  53. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002 Apr 01; 94(7):2024-32.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.